Emergent Biosolutions (NYSE:EBS) Cut to Hold at Wall Street Zen

Key Points

• Emergent Biosolutions was downgraded by Wall Street Zen from a "buy" to a "hold" and was also cut to "sell" by Weiss Ratings, leaving a MarketBeat consensus rating of Hold with an average target price of $15.00.
• The company posted a clear earnings miss, reporting EPS of ($0.43) versus expectations of $0.11 and revenue of $148.7M versus $217.5M, and analysts now expect roughly -0.63 EPS for the year.
• Shares opened at $8.29 (1‑year range $4.02–$14.06), the market cap is about $435M, and institutional investors own roughly 78.4% of the stock.

Emergent Biosolutions (NYSE:EBS - Get Free Report) was downgraded by Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued to investors on Sunday.

A number of other equities research analysts also recently weighed in on EBS. Weiss Ratings lowered Emergent Biosolutions from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Monday, March 2nd. HC Wainwright reaffirmed a "buy" rating and set a $15.00 price objective on shares of Emergent Biosolutions in a research report on Tuesday, December 16th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $15.00.

Emergent Biosolutions Stock Performance

Shares of Emergent Biosolutions stock opened at $8.29 on Friday. The business has a 50-day moving average price of $11.29 and a two-hundred day moving average price of $10.40. Emergent Biosolutions has a 1-year low of $4.02 and a 1-year high of $14.06. The company has a current ratio of 5.01, a quick ratio of 2.41 and a debt-to-equity ratio of 1.09. The company has a market cap of $435.39 million, a P/E ratio of 9.87 and a beta of 2.41.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last announced its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.11 by ($0.54). Emergent Biosolutions had a net margin of 7.08% and a return on equity of 15.86%. The business had revenue of $148.70 million during the quarter, compared to analyst estimates of $217.50 million. As a group, analysts anticipate that Emergent Biosolutions will post -0.63 EPS for the current year.

Institutional Trading of Emergent Biosolutions

Several institutional investors have recently made changes to their positions in EBS. Silver Oak Securities Incorporated purchased a new position in Emergent Biosolutions during the third quarter worth about $941,000. Allianz Asset Management GmbH grew its position in Emergent Biosolutions by 149.0% in the 3rd quarter. Allianz Asset Management GmbH now owns 279,807 shares of the biopharmaceutical company's stock worth $2,468,000 after purchasing an additional 167,423 shares in the last quarter. Geode Capital Management LLC increased its stake in Emergent Biosolutions by 108.9% in the 2nd quarter. Geode Capital Management LLC now owns 1,278,998 shares of the biopharmaceutical company's stock valued at $8,162,000 after buying an additional 666,708 shares during the last quarter. Federated Hermes Inc. increased its stake in Emergent Biosolutions by 43.6% in the 3rd quarter. Federated Hermes Inc. now owns 401,258 shares of the biopharmaceutical company's stock valued at $3,539,000 after buying an additional 121,789 shares during the last quarter. Finally, Advyzon Investment Management LLC bought a new position in shares of Emergent Biosolutions during the 2nd quarter worth approximately $90,000. Institutional investors own 78.40% of the company's stock.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company's portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent's lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.